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Ch 159B-01: Epidemiology of symptoms in the older population with advanced chronic 
disease  
The ageing population is associated with growing numbers of people suffering from a complex 
combination of chronic diseases such as heart disease, cerebrovascular disease, respiratory 
disease, cancer, frailty and neurodegenerative diseases such as dementia. This increasing 
complexity and changing pattern of illness gives rise to some particular needs at the end of life.  
In a study performed in community-dwelling older persons with advanced chronic disease 
Walke et al. (2004) reported that virtually all participants (86%) experienced at least one 
symptom and most (69%) experienced two or more symptoms. The symptoms reported 
commonly in studies are limited activity (61%), fatigue (47%) and physical discomfort (38%) 
like pain, urinary incontinence, anorexia, constipation and dyspnoea (Van Lancker et al. 2014). 
Also in people with advanced dementia, multiple clinical care needs like eating and swallowing 
disorders (from 45.9% to 85.8%), pressure ulcers (in 14.7% to 62.3%), urinary incontinence (in 
89.2%), and different types of infection (13.4% to 52.6% ) are described. Most reported 
physical symptoms at the end of life in population with advanced dementia are pain in 11.5% 
to 64.7% , shortness of breath in 8.2% to 46% and agitation in about 55% of the population 
with advanced dementia (Mitchell et al. 2004,2009; van der Steen et al. 2009; Hendriks et al. 
2014; Vandervoort et al. 2013; Sternberg et al. 2014). 
Symptoms during the last year of life in older persons are often more complicated than in 
younger patients. Older persons not only suffer from symptoms due to the underling life-
threatening illness but also from consequences of other chronic conditions like osteoarthritis, 
osteoporosis, and peripheral neuropathy. Moreover psychosocial and spiritual needs, related to 
other life events such as bereavement and not directly to the underlying life-threatening disease, 
can cause other forms of suffering. Between 27% - 66% of patients with advanced dementia 
experience psychological symptoms such as behavioural disturbances and psychosis. Also 
anxiety and depressed mood occur in 30% to 50% of the older population with cancer as well 
as with advanced dementia (Van Lancker et al. 2014, Hendriks et al. 2014). Spiritual symptoms 
as a cause of suffering are rarely studied. One recent study in patients with advanced dementia 
found only 56% of the residents die peacefully as perceived by relatives (De Roo et al. 2014).  
Geriatric palliative medicine is the medical care and management of older patients with health 
related problems and progressive, advanced disease, for whom the prognosis is limited and the 
focus of care is the quality of life. Therefore geriatric palliative medicine should focus on 
geriatric assessment, relief from pain and other symptoms and management of physical and 
psychological problems, integrating social, spiritual and environmental aspects. It should also 
recognise the unique features of symptom and disease presentation, the interaction between 
diseases, the need for safe drug prescribing and the importance of a tailored multidisciplinary 
approach for older palliative patients and their family (Pautex et al. 2010). 
A recent white paper from the European Association of Palliative Care (EAPC) reviews the 
aspects of palliative care for patients with dementia and formulates some recommendations for 
clinical practice and future research (van der Steen et al. 2014). 
In this chapter we will focus on the assessment and the management of common symptoms 
such as pain, anorexia, nausea and vomiting, constipation, delirium, depression and anxiety in 
older persons with normal and impaired cognitive function. 
  
Ch 159B-02: A palliative approach in older people 
Palliative care has been defined by the World Health Organisation as: 
“The active, total care of patients whose disease is not responsive to curative treatment. Control 
of pain, of other symptoms, and of psychological, social and spiritual problems is paramount. 
The goal of palliative care is achievement of the best quality of life for patients and their 
families.” 
This definition provides a useful framework for thinking about management in older people 
who are reaching the end of life. It should be emphasised that palliative care does not mean 
withdrawing care or not using “curative” therapies, for example, whilst an older person and 
their family may not have opted for “aggressive” interventions it may be reasonable to alleviate 
a bowel obstruction or have other surgery, if the problem is causing distress or pain.  
 
It is vital that a holistic and multidisciplinary approach is taken towards the end of life. The 
older person may benefit greatly from environmental modifications in the home such as bath 
boards or stair lifts and these interventions can decrease pain, improve independence, function 
and subsequently quality of life. As death approaches the incidence of swallowing difficulties, 
cachexia and pressure sores may increase (Ahronheim et al. 1996)  and the expertise of other 
members of the multidisciplinary team such as tissue viability nurses, speech and language 
therapists and dieticians is important.  
 
A palliative care approach ensures that symptoms are continually assessed and it is important 
that goals of treatment are regularly reviewed and recalibrated as the end of life approaches. 
This may mean, for example that the use of opioid and sedation becomes more acceptable to 
the dying older person if it means that pain is well managed, and conversely they may accept a 
degree of pain if this allows them to continue to communicate (Russell et al. 2010).  
It can be helpful to have discussions with the dying person and their families about a “ceiling 
of care” to develop a treatment escalation plan (Obolensky et al. 2010). This promotes good 
pain management by considering decisions, for example, discontinuing painful interventions 
like phlebotomy or arterial blood gas sampling. It may also reduce the risks of people 
undergoing painful and distressing transfers towards the end of life, particularly into acute care 
settings.  
Towards the end of life, the role of families and other informal caregivers becomes more vital. 
As well as providing physical care and support they may need to act as an advocate or key 
decision maker, especially if the dying older person loses the capacity to communicate. They 
may have to give information on medical comorbidities, ensure that analgesia are given 
regularly and help interpret and communicate when the person is in pain.  
 
Ch 159B-03 Assessment of symptoms and discomfort at the end of life 
As diseases become more and more complex and present with atypical symptoms, it is 
important to perform a thorough assessment of possible symptoms. Scales such as the 
Edmonton Symptom Assessment Scale and adapted versions can be helpful in examining the 
presence and the intensity of common symptoms in advanced disease (Walke et al. 2006). For 
pain assessment in the older people, please refer to chapter 159A-03. This assessment should 
be followed by extended history taking, an in depth clinical examination and where necessary, 
appropriate investigations such as a biochemical profile, full blood count or a radiology.  
Distinguishing between pain and discomfort is important in providing the best quality care to 
older people. Significant pain will usually result in discomfort, but it is important to understand 
that pain is just one of many possible causes of discomfort; for example being bored, agitated, 
cold or constipated. In addition, comfort is more than the absence of discomfort (mental or 
physical), or pain and is also closely related to the concept of quality of life.  
A number of discomfort scales have been developed for example, the Discomfort Scale–
Dementia Alzheimer Type “DS-DAT” (Hurley et al. 1992) and the End of Life in Dementia- 
Comfort Assessment in Dying scale “EOLD-CAD” a tool developed to assess comfort in 
dementia at the end of life (Volicer et al. 2001). These tools include broader concepts than pain 
tools (although many include items related to physical pain as well) and include constructs such 
as “peace”, “serenity” (EOLD-CAD) and “frightened facial expression: scared, concerned 
looking face; looking bothered fearful or troubled; alarmed appearance with open eyes and 
pleading face (DS-DAT). 
A different approach is taken in some tools, for example the Disability Distress Assessment 
Tool (DisDAT) was developed for people with severe communication difficulties and 
documents an individuals’ signs and behaviors when distressed and when they are content or 
neutral. This allows a more person-centered assessment of distress and discomfort but requires 
raters to have individual knowledge of a person’s individual response (Jordan et al. 2012). 
 
Ch 159-4 Management of pain and prevalent non-pain related symptoms in advanced 
disease 
Palliative radiotherapy and chemotherapy may be an option for older patients in order to achieve 
better symptom control but in this population careful consideration of benefits, risks and a 
careful observation for adverse events is vital. Currently, there is only limited research 
concerning palliative radiotherapy and chemotherapy in the older person.  
Good pain and symptom control must be based on the four following key domains: physical, 
psychological, social and spiritual wellbeing. If one domain is forgotten, controlling pain and 
other symptoms becomes even more challenging.  
When considering symptom control at the end of life, it is important to understand that listening 
and being present may be more important than just prescribing medication. Explaining the 
reasons for symptoms and the planned actions to alleviate or resolve them is often enough to 
reassure patient and family members. Non-drug methods, as discussed below, may have an 
important place in the treatment of the older palliative patient. In case of pharmacological 
therapy, a careful follow-up of the possible adverse side effect is essential. 
In the next part of this chapter, we will briefly consider the management of common symptoms 
in the older population.  
Pain  
For the basic principles of pain treatment in older people, please refer to chapter 159-04. 
In palliative medicine, special attention should be paid to the ‘total pain’ concept, exploring the 
non-physical components that may influence the perception of pain and suffering. 
Psychological distress including depression and anxiety is common in older people who may 
be nearing the end of life. In particular, at the end of life, people may experience existential 
distress - feelings of hopelessness, meaninglessness, or anxiety over dying. A holistic, 
multidisciplinary approach, such as that provided by palliative care services, may offer 
meaningful support. 
Anorexia – cachexia syndrome 
The anorexia-cachexia syndrome (ACS) is characterised by anorexia, malnutrition, weight loss, 
asthenia and chronic nausea. It is one of the most frequent symptoms in palliative care and the 
cause of death in more than 50% of the cases. Moreover anorexia is an independent predictive 
factors for successful treatment and patient quality of life. ACS is characterised by a complex 
underlying pathophysiology (Argiles et al. 2003). Possible underlying pathogenetic factors in 
this syndrome include circulating cytokines such as interleukin 1(IL-1), IL-6, tumour necrosis 
factor-, interferon  and , secreted by the tumour or the host itself. Recent studies show that 
these factors are also present in patients with terminal heart failure, terminal chronic obstructive 
lung disease and possibly in patients with dementia.  
The treatment of ACS is still a challenge. Dietary advice, enteral and parenteral nutrition have 
not been shown to influence the wellbeing and survival of the cancer patient. Synthetic 
progestogens are a class of drugs with possible benefit in the ACS. These molecules induce a 
significant increase in the appetite and sometimes also increase the weight of the patient. 
However those drugs have not been shown to improve lean body mass, functional activity or 
quality of life (Ruiz et al. 2013). Moreover they have important side effects such as fluid 
retention and high risk of phlebothrombosis: these are often a contraindication to their use in 
older patients. Another effective agent, corticosteroids may be useful for their rapid beneficial 
effects on appetite, mood and quality of life. However, because of their side effects (muscle 
atrophy, increased risk of glucose intolerance and candida infection) and rather short term 
effect, alternating administration is recommended. Among the drugs with confirmed clinical 
efficacy, COX-2 inhibitors and anabolic agents, such as oxandrolone, have been shown to 
achieve good results, however no specific studies are available in older people. Investigational 
drugs with so far proven clinical effectiveness include ghrelin and ghrelin mimetics, SARMs, 
myostatin inhibitors and β-adrenoceptor agonists (Mantovani et al. 2013). 
Fatigue 
Fatigue is often present in people receiving palliative care. The unusual need for increased rest 
and sleep, difficulties with concentration, a diminished attention and impaired problem solving 
ability often influence the quality of life. Fatigue is often accompanied by complaints as 
hypotension, bradycardia, dyspnoea and dizziness. The aetiology is often multifactorial. 
Treatment focusses on the management and correction of possible causal factors. Supportive 
measures such as an activity diary, including rest, adapting the daily routine and limiting the 
frequency of visits may be necessary to augment the quality of life. Corticosteroids or synthetic 
progestogens may be considered but with the same cautions as when they are used in cachexia 
(Sherman et al. 2003).   
Dyspnoea 
Dyspnoea is a subjective feeling of difficulty in breathing and has multiple underlying causes. 
These are often multifactorial, may not have a specific treatment and thus symptomatic 
treatment is required to maintain quality of life. 
Non-pharmacological support is important as severe dyspnoea is often frightening and the 
induced anxiety can further exacerbate the symptom. Listening to patients and their families, 
careful explanation and reassurance can be helpful for the patient. Relaxation, breathing 
exercises and help with expectoration of secretions offered by a physiotherapist is important. 
The use of oxygen is often controversial and only necessary if hypoxia can be demonstrated. 
Three classes of drugs are useful as pharmacological treatment namely opioids, corticosteroids 
and benzodiazepines. Opioids act by reducing the sensitivity of the respiratory centre and the 
central perception of dyspnoea. A Cochrane and another recent review shows evidence for the 
use of oral and parenteral morphine on the intensity of breathlessness but not on exercise 
capacity (Jennings et al. 2003, Johnson et al 2014). Corticosteroids are preferentially used for 
their anti-inflammatory effects. Benzodiazepines (with preference for short acting) are 
important drugs to control anxiety.  
Nausea and vomiting 
Table 2 gives pharmacological treatment options for nausea and vomiting from various causes. 
The first line treatment in opioid-induced vomiting is metoclopramide, often given 
prophylactically (Neoh et al. 2014). 
In patients with nausea, oral medication can be tried but often and especially in vomiting 
patients, alternative routes are needed. The preferred route in this patients is the subcutaneous 
way using a syringe driver. Specialist detailed information concerning this mode of drug 
administration in palliative care is available (Dickman and Schneider 2011). 
In addition, non-pharmacological treatment is very important in managing nausea and vomiting. 
Avoidance of irritating smells, creating a quiet environment, offering fresh air, managing 
anxiety, avoiding movements and regular mouthwashes with clear fluids, are small 
interventions that can give relief.  
Pathophysiological 
pathway 
Aetiology Pharmacological treatment 
Gastro-intestinal  





Metoclopramide 10 – 20 mg/8h PO, 
SC,IV 
Domperidone 10 – 20 mg/6à8h PO 
Dexamethasone 5-20mg/24h SC,IV 
Somatostatin/octreotide 0.3-1.5mg/24h 
SC 











Metoclopramide 10 – 20 mg/8h PO, 
SC,IV 
Domperidon 10 – 20 mg/6à8h PO 
Alizapride 200-300mg/24h SC,IV 
Chlorpromazine 25-75mg/8u PO 
Haloperidol 2-10mg/24u PO, SC, IV 
5HT3-antagonist SC, IV, PO 
Stimulation of the 
vestibular apparatus 
Cerebral tumour, 
antibiotics, movements  
Hyoscine hydrobromide 0.25-1.5mg/24h 
SC 
Promethazine 25-50mg/12h SC 




pressure by cerebral 
tumour, metastasis, 
cerebral oedema  
Dexamethasone 5-20mg/24h SC,IV 
Hyoscine hydrobromide 0.25-1.5mg/24h 
SC 
Lorazepam 4 mg/24u PO,SC,IV 
Alprazolam 0.25-1mg/8u PO 
Table 2: Pharmacological treatment of nausea and vomiting by underlying causes  
Constipation 
Constipation is a common problem in over 50% of people receiving palliative care, increasing 
to a prevalence of 80-90% in those on opioid therapy. A recent review on the treatment of 
constipation in palliative care concluded that there is little evidence for conventional 
pharmacological treatments for constipation due to insufficient randomized controlled trials. 
Subcutaneously administered methylnaltrexone was found to be effective and well tolerated 
with limited side effects (Clemens et al. 2013). A European Consensus Group on constipation 
in palliative care (2008) recommended a combination of a softener and stimulant laxative but 
the choice should be made on an individual basis. 
Delirium 
Most people who are dying will experience delirium. Given that the major risk factors for 
delirium are increasing age, frailty, pre-existing cognitive impairment and infection, it is very 
common in older people with terminal illness (Inouye et al. 2014). Delirium is a frightening 
experience, both for the person experiencing it and their families; it also leads to significant 
management challenges for staff. The core symptoms are an abrupt onset with fluctuating 
course, alterations in the sleep-wake cycle and impaired level of consciousness. Agitated or 
hyperactive delirium is particularly common in people who are dying and is accompanied by 
frightening perceptual disturbances of hallucinations. A palliative care approach is compatible 
with seeking and treating the cause of the delirium, for example giving an antibiotic for a urinary 
tract infection may provide symptomatic relief. Non-pharmacological interventions can be very 
effective and safer in older people. There is good evidence that multi-component interventions 
involving re-orientation, a quiet and well-lit environment, enhancing vision and hearing by 
ensuring glasses and hearing aids are available and early mobilization reduces the risk and 
length of delirium (Inouye et al. 2014).  In cases of great distress it may be necessary to use 
medication. Conducting clinical trials in delirium is challenging. A recent Cochrane review has 
found that low dose haloperidol (0.5-1.0mg, every 2-12 hours, carefully titrated to response and 
to avoid over-sedation) may be effective in reducing the symptoms of delirium. Older people 
are at higher risk of adverse side effects from neuroleptics, for example over sedation, aspiration 
and stroke and neuroleptics should be used for the shortest possible time and at the lowest 
effective does (Jackson-Siegal et al. 2004). There is less evidence for the effectiveness of 
benzodiazepines in older people with delirium and their use is not recommended (Young et al. 
2010).  
Depression  
Depression is caused by the complex interaction of biological factors, for example Parkinson’s, 
stroke and other neurodegenerative diseases, thyroid dysfunction and anaemia, with 
psychological challenges, such as loss and grief and social factors such as loneliness and loss 
of independence. As the end of life approaches the risk of developing depression increases 
further, for example in a large American population cohort of older people, more than 70% of 
colorectal cancer outpatients were diagnosed with depressive disorder (Zhang and Cooper 
2010).  
Depressed mood and sadness may be an appropriate response to imminent death. Standard 
clinical diagnostic criteria for depression such as DSM IV or ICD 10 may not be useful towards 
the end of life as they rely heavily on the presence of somatic symptom such as loss of appetite 
or sleep problems. Multidisciplinary assessment, for example input from an old age psychiatrist 
or psychologist may be very helpful in disentangling these problems.   
Management of depression in older people who are dying requires a bio-psychosocial approach. 
Ensuring that pain and other physical symptoms are treated adequately may improve mood 
(Husebo et al. 2014). Psychological and supportive therapy can be effective, even in people 
with early cognitive impairment. Psychotherapy is effective for depressive symptoms in 
advanced cancer although evidence for effectiveness in major depression is lacking (Akechi et 
al. 2008). There is good evidence that antidepressants are effective in patients with advanced 
cancer (Rayner et al. 2011 ). The evidence for other life limiting illnesses is less strong, however 
pharmacotherapy remains the mainstay of treatment in major depression. In older people, 
selective serotonin re-uptake inhibitors are the antidepressant of choice as they are effective as 
tricyclic antidepressants but have a safer side effect profile (Rayner et al. 2011). Tricyclic 
antidepressants are potently anticholinergic and can cause tachycardia, constipation, dry mouth 
and have effects on cognitive function- all of which highly undesirable in the older person.  
Anxiety 
Anxiety causes a broad range of symptoms both psychological, for example worry, 
distractibility or rumination, and physical such as restlessness. These can cause a high level of 
distress for patients and their families and should be seen as more than just inevitable at the end 
of life. Anxiety can be precipitated or worsened by the underlying physical problem; pain, 
dyspnoea, delirium and infection are commonly associated. Anxiety can also be caused by 
existential distress and other issues: anticipatory grief of dying, feelings of lack of control, 
claustrophobia and concerns about intimacy.  
There have been few studies on how to best manage anxiety in older people who are dying. A 
calm, listening empathic approach is sometimes all that is required. Religion may have an 
important part in the life of the older person and involving faith leaders in support and 
addressing unmet spiritual needs can alleviate patients’ distress (Stanley et al. 2008).  
Pharmacological management of anxiety may involve treating the underlying cause, for 
examples ensuring adequate analgesia for pain or giving oxygen and opioids in dyspnoea. 
Benzodiazepines can be useful if prescribing is carefully considered. Shorter acting 
benzodiazepines are safer but older people are particularly at risk of side effects such as falls, 
over-sedation and confusion. Midazolam infusion is widely used in terminal agitation and 
anxiety in the terminal phase of life.  
Dry mouth 
People receiving palliative care will often experience a dry and painful mouth. Frequent causes 
include the use of drugs with anticholinergic effects, opioids, dehydration, decreased food 
intake and an increase in mouth breathing. Health care workers should especially be aware of 
these problems in the older person who is functionally dependent.  
Good oral hygiene should consist of regular cleaning of the teeth or dentures and mouthwashes 
with chlorhexidine 0.2%. In disabled patients mouth care may be needed every two hours. 
Contributing medications should be stopped if possible and the patient should be offered regular 
drinks. Artificial saliva or stimulation of the salivary glands by citrus sweets, acid drops and 
chewing gum can be effective. Candida stomatitis is a frequent complication in palliative 
patients. Treatment with nystatin suspension or fluconazole is indicated (Sykes, 2003). Other 
plaques in the mouth are often challenging. Careful cleaning of the tongue with a scraper or 
brush, using yogurt or vitamin C tablets before cleaning can be helpful. Hydration of the lips 
by using Vaseline or hydrating lipstick can also diminish the sense of dry mouth. 
(http://www.who.int/hiv/pub/imai/genericpalliativecare082004.pdf)  
Care in the last days of life (terminal care) 
The correct recognition and management of the last days of life is very important for the patient 
and their family as this will influence the family’s bereavement and the way they will cope with 
the loss of their loved one. The dying phase can often be diagnosed through a gradual increase 
in weakness and drowsiness, a decline in mental capacity, a refusal of food or fluids, irregular 
breathing, cold and mottled extremities and often an exacerbation of existing symptoms as pain, 
anxiety or restlessness (Kehl et al. 2013). These symptoms are comparable with those in 
younger patient populations (Rashidi et al. 2011). In this terminal period a review of the 
medication and non-pharmacological management is necessary. Drugs that are no longer 
necessary for symptom relief should be withdrawn and the route of administration should be 
revised if the patient is not able to swallow anymore. 
Frequent symptoms in the last hours of life are pain, restlessness, agitation and death rattle. 
Death rattle is caused by respiratory secretions which cannot be cleared anymore. This noisy 
breathing may be more distressing for the family than for the patient. Giving families 
information about the origin of the death rattle is the first step in managing this difficult 
symptom. A current review of the literature showed that there is no evidence supporting the use 
of anticholinergic drug at the end of life (Lokker et al. 2014). However, another recent review 
suggested that this observation could be confuted by the prophylactic use of these drugs 
(Mercadante 2014). Anticholinergic medication as hyoscine hydrobromide (0.5 mg/4h SC, IM) 
or glycopyrronium (200 to 400 µg given every 4 to 6h SC,IM) may be considered if the aim is 
to diminish the production of respiratory secretions. These drugs can be added to the syringe 
driver. In the last days of life, other subcutaneous drugs frequently used to alleviate symptoms 
include opioids such as morphine and psychotropic medications such as midazolam and 
sometimes haloperidol.  
 
Ch 059-4 Conclusion  
The increasing complexity and challenging patterns of illnesses gives rise to complex  needs at 
the end of life. Symptoms are often not just physical, but also encompass potentially unpleasant 
emotional and spiritual distress. Symptom control starts with an optimal assessment of 
symptoms using adequate tools, adapted to the cognitive and communicative status of the 
person. Little or no evidence is available for the non-pharmacological and pharmacological 
treatment of symptoms in the older person. Guidelines developed by expert panels of national 
societies may be of help in optimising the treatment. The management of symptoms at the end 
of life in older people requires excellent knowledge of geriatric medicine, palliative care, 
empathy, good communication skill and great compassion. 
 
